Products for Research Use Only

ATX968

CAT: 0804-HY-156784-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-156784-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ATX968 (example 31) is an orally active, potent and selective inhibitor of ATP-dependent RNA helicase A (DHX9), with the EC50 of 0.054 μM in circBRIP1. ATX968 results in robust and durable tumor growth inhibition or regression in mouse xenograft studies with MSI-H/dMMR colorectal cancer cell lines[1][2][3].
CAS Number
2973395-71-8
Product Name Alternative
DHX9-IN-2
UNSPSC
12352005
Target
DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dhx9-in-2.html
Concentration
10mM
Purity
99.61
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
ClC1=CC(NC(C2=CC(C3=NC=CC=C3C)=CS2)=O)=CC(NS(C)(=O)=O)=C1
Molecular Formula
C18H16ClN3O3S2
Molecular Weight
421.92
References & Citations
[1]DANIELS Matthew H., et al. Preparation of imidazopyridines, thienopyrimidines, pyrrolopyrimidines and related heterocycles as inhibitors of RNA helicase DHX9 useful in treatment of cancers. World Intellectual Property Organization, WO2023154519 A1 2023-08-17|[2]Castro J, et al. A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. Cancer Res. 2025 Feb 17;85 (4) :758-776.|[3]Castro J B, et al. DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2[J]. Cancer Research, 2024, 84 (6_Supplement) : 3908-3908.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported